Rock Springs Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Rock Springs Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-90,000	Closed	-$5.45M	–	135
2018 Q3	$5.45M	Hold	90,000	–	–	0.2%	114
2018 Q2	$4.77M	Hold	90,000	–	–	0.18%	119
2018 Q1	$5.22M	Buy	+90,000	New	+$5.6M	0.22%	116
2015 Q2	–	Sell	-7,050	Closed	-$2.86M	–	118
2015 Q1	$2.86M	Buy	+7,050	New	+$2.98M	0.27%	90
2014 Q4	–	Sell	-720	Closed	-$246K	–	95
2014 Q3	$246K	Buy	+720	New	+$214K	0.04%	83

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Rock Springs Capital Management's ADVM Position: Q4 2018 in Review

Rock Springs Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2018, closing a stake of 90,000 shares — an estimated $5.45M sold.

Rock Springs Capital Management first reported a position in ADVM in Q3 2014 and held it in 5 quarters. The position peaked at $5.45M in Q3 2018. 86 funds tracked by Wall St. Rank hold ADVM as of Q4 2018.

Rock Springs Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2018 after selling out during the quarter.
Rock Springs Capital Management sold 90,000 Adverum Biotechnologies shares in Q4 2018, an estimated $5.45M.
Rock Springs Capital Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 5 quarters.
Rock Springs Capital Management's Adverum Biotechnologies position peaked at $5.45M in Q3 2018.
86 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2018.

Based on Rock Springs Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.